secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001193125-23-270462
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 1.02
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotechnology enters $300M at-the-market equity facility with TD Cowen
--------------------------------------------------------------------------

- New Sales Agreement allows Vir to sell up to $300M of common stock through TD Cowen as agent.
- Commission of up to 3.0% on gross proceeds; Cowen may use customary at-the-market methods.
- Prior 2020 sales agreement with TD Cowen terminated; no shares were sold under the prior facility.
- Shares sold under existing S-3 shelf registration statement filed November 3, 2023.
- Company not obligated to sell any shares; facility provides optional capital-raising flexibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523270462/0001193125-23-270462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000119312523270462/d567220d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-270462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer